Skip to main content
IPGP
NASDAQ Manufacturing

IPG Photonics Q3 Revenue Up 15% to $287.5M, EPS $0.47; Q4 Guidance $265M-$295M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Semiconductor Stocks · Technology
Sentiment info
Positive
Importance info
7
Price
$72.91
Mkt Cap
$3.101B
52W Low
$68.27
52W High
$155.82
52W Position info
6.8% above low
Off High info
53% below high
Rel. Volume info
0.9× avg
Market data snapshot near publication time

IPGP is trading near its 52-week low of $68.27 (6.8% above the low).

Summary

IPG Photonics grew Q3 revenue 15% to $287.5M and more than doubled net income to $20.3M ($0.47 per diluted share), but Q4 guidance of $265M-$295M implies little sequential growth and excludes the pending Lumibird Medical acquisition.


Key Events · Earnings and Guidance · IPGP

  • Q3 Revenue Grows 15% to $287.5M

    Revenue rose to $287.5M from $250.8M a year ago, above the midpoint of guidance, with Industrial Solutions up 12% to $239.5M and Advanced Solutions up 33% to $48.0M.

  • Net Income More Than Doubles

    GAAP net income was $20.3M, or $0.47 per diluted share, versus $7.5M and $0.18 a year ago; adjusted EPS was $0.61 and adjusted EBITDA $51.5M, up 39%.

  • Gross Margin Boosted by Tariff Refunds

    GAAP gross margin of 40.7% and adjusted gross margin of 41.0% included $5.0M in net tariff refunds recorded in the period, partially offset by lower fixed cost absorption.

  • Q4 Guidance Brackets Current Quarter

    Q4 2026 revenue is guided to $265M-$295M with adjusted EPS of $0.30-$0.60 and adjusted EBITDA of $33M-$50M; the range assumes no contribution from Lumibird Medical.


Analysis · IPGP · Manufacturing

Revenue of $287.5M beat the midpoint of guidance and rose 15% year over year, while GAAP EPS came in at $0.47 versus $0.18 a year ago and adjusted EPS at $0.61. The margin story is the real change: gross margin of 40.7% included $5.0M of net tariff refunds, and adjusted EBITDA jumped 39% to $51.5M. Against that, the Q4 guide of $265M-$295M brackets the just-reported quarter and assumes no contribution from the pending Lumibird Medical deal, so the growth rate is set to flatten unless the acquisition closes and adds revenue. The $710.7M cash balance plus $215.3M in short-term investments comfortably funds the €300M cash purchase price previously disclosed.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 35.1% of the 2636 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IPGP was trading at $72.91 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $3.1B. The 52-week trading range was $68.27 to $155.82. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IPGP - Latest Insights

IPGP
Nov 03, 2026, 4:31 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $74.65
Real-time Price: $65.31 info
Change: -$9.34 (-13%) info
Market Cap: $2.776B info
IPGP
Nov 03, 2026, 8:00 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $72.91
Real-time Price: $65.31 info
Change: -$7.60 (-10%) info
Market Cap: $2.776B info
IPGP
Sep 08, 2026, 4:39 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $79.56
Real-time Price: $65.31 info
Change: -$14.25 (-18%) info
Market Cap: $2.776B info
IPGP
Aug 04, 2026, 4:22 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $94.07
Real-time Price: $65.31 info
Change: -$28.76 (-31%) info
Market Cap: $2.776B info
IPGP
Aug 04, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $93.00
Real-time Price: $65.31 info
Change: -$27.69 (-30%) info
Market Cap: $2.776B info